What's hAPPening at synapses? The role of amyloid b-protein precursor and b-amyloid in neurological disorders
INTRODUCTION
Since the discovery of amyloid-beta (Ab) plaques by Alois Alzheimer in 1906 in a patient with presenile dementia, intense investigation by the scientific community has focused on understanding the normal and pathological mechanisms underlying Ab synthesis and accumulation. Ab is a small hydrophobic peptide that is released after processing of a large transmembrane precursor protein, amyloid b-protein precursor (APP), which localizes to membranous organelles and the post-synaptic densities of select neurons. 1 Processing of APP by secretases produces soluble N-terminal domains (sAPPa and sAPPb), Ab and carboxy-terminal fragments, and each of these catabolites possesses unique functions. 2 Despite a century of investigation, much remains to be elucidated in regards to the synthesis, processing and function of APP and its catabolites in normal as well as disease states. Accumulating evidence suggests that synaptic dysregulation of APP production and cleavage determines the level of Ab in the brain interstitial fluid thus contributing to the pathogenesis of amyloidogenic disorders. 3, 4 Thus, a clearer understanding of the synaptic regulation of APP will provide novel targets for therapeutic intervention.
SYNAPTIC SYNTHESIS AND PROCESSING OF APP
The synthesis and processing of APP and Ab involve a combination of transcriptional, post-transcriptional, translational and post-translational events. 5 The gene that codes for APP is located on human chromosome 21 and codes for APP mRNA (mouse chromosome 16; App mRNA). 6, 7 Numerous RNA binding proteins interact with cis-regulatory elements in APP mRNA to mediate transcript stability and translation. 5 Of note, fragile X mental retardation protein (FMRP), which is an RNA binding protein found at the post-synaptic density (PSD) and is involved in the transport, localization and translational regulation of a subset of dendritic mRNAs, 8 binds to and represses the translation of App mRNA through an mGluR 5 -dependent signaling pathway. 4, 9, 10 Localization of FMRP to the PSD remains somewhat controversial as there is a growing body of evidence that FMRP represses translation by binding to mRNAs in the cytoplasm or on ribosomes undergoing translation. High-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation (HITS-CLIP) identified App mRNA as interacting with FMRP in mouse brain polyribosomes. 11 APP production is developmentally regulated with expression increasing during neuronal differentiation, maximal during synaptogenesis and declining when mature connections are established. [12] [13] [14] Maximal APP expression coincides with the critical period of sensory development in rodents (postnatal weeks 2-6). 15 Alterations in the expression or localization of RNA binding protein throughout development would be expected to have a significant effect on the synthesis and processing of APP. For example, FMRP expression is developmentally regulated in the neonatal brain where it peaks at the end of the first postnatal week and declines thereafter. 16 Thus, as FMRP decreases during synaptogenesis, APP expression increases. These data agree with our findings that FMRP translationally represses App mRNA, 4 which accounts for increased APP production during synaptogenesis when FMRP levels are declining. Studies in adult animals indicate that FMRP is ubiquitously expressed and declines in an age-dependent manner. 17, 18 Decreased expression of FMRP with aging is expected to contribute to excess APP and Ab production.
APP is cleaved by b-and g-secretases to generate Ab, the predominant protein found in the senile plaques characteristic of Alzheimer's disease (AD) and Down's syndrome (DS). 19 b-secretase (aka: memapsin 2; BACE-1) and g-secretase (catalytic component is presenilin) are transmembrane proteins containing aspartic protease catalytic domains that cleave APP to generate the amino-and carboxy-terminal ends, respectively, of Ab. Ab is an internal fragment of APP beginning about 99 residues from the carboxy-terminus and extending from the extracellular domain into the middle of the hydrophobic, membrane-spanning domain of the precursor protein. Alternate APP metabolism can involve cleavage by a-secretase (ADAM family members) within the Ab region, which precludes formation of the amyloidogenic peptide and releases a neuroprotective 82 kDa soluble fragment (sAPPa) into the extracellular fluid. 20 The amyloidogenic b-secretase pathway is favored when APP is overexpressed or mutated. 21 Because of differential g-secretase cleavage at the carboxyterminal end of Ab, different forms of b-amyloid are generated. 22 Although Ab is found in normal biological fluids throughout life, it becomes toxic after overexpression and/or assembly into oligomeric aggregates. 23 In AD, there is excessive production and/or reduced clearance of Ab leading to the accumulation of dense amyloid plaques. Therefore, strategies to halt or retard AD progression have sought to promote sAPPa formation (increase a-secretase activity) or prevent Ab formation (decrease b-secretase activity).
FUNCTION OF APP AND CATABOLITES AT SYNAPSES
APP functions in synapse formation, dendritic spine formation, synaptic transmission, learning and memory, neurite outgrowth, motility and development. 24 APP homodimerizes as well as interacts with sAPP catabolites and other receptors to influence downstream signaling events involved in synaptic function. For example, sAPPa serves a neuroprotective function by disrupting APP dimers in the membrane to prevent starvation-induced cell death. 25 APP and APP-like proteins anchor cytoplasmic polyadenylation element binding factor to membranes and promote polyadenylation-induced translation. 26 sAPPa increases de novo protein synthesis in rat synaptoneurosomes, 27 enhances long-term potentiation (LTP) 28 and shifts the frequencydependency for induction of long-term depression (LTD). 29 Although there is only a 17-amino acid difference between the differentially processed N-terminal fragments, sAPPa possesses synaptotrophic and neuroprotective activities while sAPPb can be toxic. 30 sAPPb binds to the death receptor 6 (DR6) to trigger axon degeneration.
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A 104-amino acid carboxy-terminal fragment generated by b-secretase cleavage of APP contains the Ab region and has been shown to impair spatial learning and maintenance of LTP in mice. 32 Further cleavage with g-secretases produces intracellular carboxy-terminal fragments of APP and varied length forms of Ab. APP carboxy-terminal fragments function in phosphorylation, protein-protein interaction, apoptosis and cell signaling. 30 Ab increases LTD, inhibits LTP and causes membrane depolarization and calcium influx. 33, 34 Ab binds to numerous cell surface receptors including APP and NMDAR. 35 Lateral diffusion and accumulation of Ab at excitatory synapses causes clustering of the peptide resulting in reduced mobility and increased activity of mGluR 5 . 36 Ab activates two pivotal signaling molecules GSK3b 37 and mTOR 38 with extensive roles in AD pathology. 39, 40 We hypothesize that Ab contributes to synaptic dysfunction through modulation of local protein synthesis at synapses (Figure 1 ). Treatment of primary cultured neurons with Ab increases the expression of several dendritic proteins including APP, Map1B and RhoB. 41 The Ab 1-42 -mediated increase in dendritic APP can be blocked with an mGluR 5 antagonist or with the translational inhibitor anisomycin. Conversely, treatment of the cell culture medium with an anti-Ab antibody reduces dendritic APP expression. 41 Our data, in conjunction with previous reports demonstrating that Ab increases APP in neuronal hybrid cells, 42 induces Ab secretion from cultured rat cortical neurons, 43 enhances mGluR 5 receptor signaling in astrocytes, 44 and induces clustering and activation of mGluR 5 , 36 support the existence of an Ab-driven positive feedback loop whereby Ab stimulates mGluR 5 signaling resulting in increased synaptic synthesis of APP, which provides more target for amyloidogenic processing.
Despite these advances, much remains to be learned regarding the normal and pathological functions of APP and its catabolites at synapses. Of interest are the consequences of disrupting APP homodimer interactions between the pre-and post-synaptic compartments by secretase activity at the plasma membrane. Disruption of these inter-cellular bridges would be predicted to affect downstream signaling, synaptic transmission and protein translation. As sAPPa is known to increase protein synthesis and enhance LTP, while Ab increases LTD and causes membrane depolarization and calcium influx, it is expected that nonamyloidogenic versus amyloidogenic processing at the synapse would differentially affect synaptic activity. Also of interest is the pathogenic role of soluble complexes of Ab, Ab-derived diffusible ligands. These oligomeric structures block LTP, target and functionally disrupt specific synapses, and are now widely accepted as causing the cognitive deficits and neurodegeneration observed in AD. 45, 46 APP AND Ab IN NEUROLOGICAL DISEASE Dysregulated levels of APP and its catabolites are implicated in several neurological disorders including AD, fragile X syndrome (FXS), DS, autism, epilepsy and Parkinson's disease (PD) as well as in response to brain injury ( Figure 2 ). AD and PD are typically considered aging disorders while DS, FXS and autism are developmental. All of these conditions are associated with cognitive deficits and lower seizure thresholds, albeit neuritic plaques have only been observed in AD, DS, epilepsy and PD. Much remains to be learned regarding the role of soluble catabolites of APP in neurological disorders. It is probable that these fragments have a pivotal role in the cognitive and seizure phenotypes associated with FXS and autism where plaque deposition has not yet been observed. Below we describe several disorders that exhibit aberrant levels of APP and/or Ab and discuss how these proteins may influence disease progression.
Alzheimer's disease AD is a progressive form of dementia characterized histologically by Ab plaques, neurofibrillary tangles and neuronal cell death. AD, along with stroke, is the third most common cause of death in the US afflicting B7% (age 65-74), 53% (age 75-84) and 40% (age 85 and older) of the population. 47 There are currently no cures or definitive diagnostic tests for AD. In a small percentage of cases, AD is directly associated with specific genetic mutations in APP (chromosome 21), presenilin 1 (chromosome 14) or presenilin 2 (chromosome 1); however, in the vast majority of cases the cause of the disease is unknown. Ab plaques are the classical pathological hallmark of AD. There are also decreased levels of sAPPa in the cerebrospinal fluid (CSF) of sporadic AD patients 48 and in familial AD patients with the inherited Swedish APP 670/671 mutation. 49 Defective synaptic function occurs early in the disease before substantial neuronal loss. 50 These data suggest that exacerbated amyloidogenic processing at the expense of decreased nonamyloidogenic processing promotes Ab accumulation and synapse failure before Ab plaque accumulation in AD. mGluR, Homer, Shank and PSD95 proteins form complexes at the PSD. 51 Soluble Ab can disrupt these scaffolding protein interactions resulting in decreased levels of Homer1b, Shank1 and PSD95 at the synapse and thinning of the PSD. 52, 53 As scaffolding proteins recruit and anchor receptors at the PSD, excessive Ab could cause synapse failure in AD by altering the molecular composition of the PSD and hence downstream signaling. In support of this theory, cultured Tg2576 neurons, which overexpress Ab, exhibit reduced PSD95 expression that is associated with decreased glutamate receptor subunit GluR1a and fewer post-and pre-synaptic compartments. 54 The oligomeric form of and treatment time with Ab affect downstream signaling. Acute treatment with oligomeric Fragile X syndrome FXS is the most prevalent form of inherited intellectual disability, affecting 1 in 4000 males and 1 in 8000 females, and is the leading known genetic cause of autism. 56 This X-chromosome-linked disorder is characterized by moderate-to-severe mental retardation (overall IQo70), autistic-like behavior, seizures, facial abnormalities (large, prominent ears and long, narrow face) and macroorchidism. 57 In the majority of cases, FXS is caused by an expansion of a CGG trinucleotide repeat (4200) in the promoter region of the fragile X mental retardation (Fmr1) gene, which results in methylation of the promoter and lack of translation of FMRP. At the neuroanatomical level, humans with FXS, as well as knockout mice for the Fmr1 gene, have an overabundance of long, thin, tortuous post-synaptic spines with prominent heads and irregular dilations resembling the spines observed during normal, early neocortical development. 58 The increased length, density and immature morphology of dendritic spines in FXS suggest an impairment of synaptic pruning and maturation. App mRNA and Ab levels are elevated in Fmr1 KO mice suggesting a pathogenic role in the disease. 4, 59 Consistent with this hypothesis, characteristic FXS phenotypes of audiogenic seizures, anxiety, the ratio of mature versus immature dendritic spines and mGluR-LTD are partially or completely reverted to normal in Fmr1 KO mice after removal of one App allele. 41 The lack of FMRP expression in FXS would predict increased APP and Ab expression throughout development as well as an increased incidence of AD. The only abnormal neuropathological observations in human FXS brain to date have involved impaired synaptic pruning and maturation; 60 however, a very limited number of aged FXS brains have been studied. [61] [62] [63] It is difficult to assess cognitive decline in mentally retarded individuals; however, fragile X-associated tremor/ataxia syndrome is associated with dementia and AD pathology. 64, 65 There is decreased plasma Ab 1-42 in full-mutation FXS males and a trend for increased brain Ab. 41 These data strongly suggest that normalization of APP and Ab levels will improve FXS phenotypes.
It remains to be determined which APP catabolites promote specific disease phenotypes. For example, the overproduction of APP in FXS, in the absence of the translational repressor FMRP, is predicted to increase amyloidogenic processing. Decreased levels of synaptic sAPPa, which promotes synapse maturation, could contribute to the overabundance of immature dendritic spines observed in FXS while increased levels of Ab could stimulate additional APP production through mGluR 5 activation. Both metabolites likely disrupt receptor/scaffolding protein interactions, and altered mGluR 5 -Homer scaffolds are known to contribute to FXS phenotypes. The binding of the long isoforms of Homer (Homer1b and Homer 1c) to group 1 metabotropic glutamate receptors (mGluRs) facilitates, while the short Homer1a reduces, coupling with signaling molecules. 66 For example, Homer1b and Homer 1c link mGluR 5 to MAPK ERK67 as well as to the phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of Figure 1 . An Ab-mediated positive feedback loop at synapses. APP synthesis occurs through a FMRP-and mGluR 5 -dependent pathway 4 providing template for secretase cleavage to produce Ab and other metabolites. Renner et al. 36 showed that Ab oligomers cause dynamic redistribution of mGluR 5 to synapses and thus facilitate increased mGluR 5 signaling. 36 We have found that Ab stimulates dendritic APP synthesis, which can be blocked with MPEP or anisomycin indicating that a mGluR 5 -and protein translation-dependent pathway is involved. 41 b-secretase interacts with APP at both the cell surface and in endocytic compartments, 157, 158 which can result in increased cleavage. These data strongly suggest the existence of a positive feedback loop whereby translation of APP results in increased target for amyloidogenic processing and release of Ab, which then stimulates cell signaling through mGluR 5 to stimulate additional dendritic translation of APP. 41, 46 Ab likely activates other signaling pathways, also, as oligomers interfere with NMDAR function and trafficking, 159 bind to cellular prion protein 160 and cause endocytosis of AMPAR subunits. 161 Co-stimulation of mGluR 5 and NMDAR is required for NMDAR potentiation of excitatory synaptic transmission. 162 The NMDAR-mediated component of the LTP is lost in mGluR 5 KO mice. 163 Thus, these receptors can act synergistically. APP can dimerize with itself as well as with APP-like proteins. 164 Thus, altered APP and Ab levels could mediate synaptic dysfunction through multiple pathways. This model suggests that secretase inhibitors and anti-Ab passive immunotherapy, which are currently under study for the treatment of AD, may be applicable to FXS, and that mGluR 5 inhibitors, which are in clinical trials for FXS, may be beneficial in the treatment of AD.
rapamycin (mTOR) pathway. 68 In Fmr1 KO mice, mGluR 5 is less associated with Homer1b and Homer 1c and more associated with Homer1a resulting in decoupling of mGluR 5 from PI3K-mTOR. 68, 69 Homer2 and Homer3, but not Homer1, interact with APP and inhibit both amyloidogenic and nonamyloidogenic processing, decrease levels of cell surface APP and inhibit the maturation of BACE-1 and Ab production. 70 Soluble Ab disrupts Homer scaffolding protein interactions and causes redistribution of mGluR 5 at the PSD. 36, 52 Thus, APP or Ab-mediated alterations in mGluR 5 /Homer interactions in FXS could affect multiple downstream signaling pathways to promote disease progression. Group 1 mGluRs are upstream of two pivotal signaling pathways, PI3 kinase/Akt/mTOR/p70S6K and Ras/MAPK/p90S6K, that positively influence protein synthesis. Down's syndrome DS, or trisomy 21, is a developmental disorder characterized by an extra copy chromosome 21, which includes the APP gene. Individuals with DS overexpress APP mRNA by four-to five-fold, deposit extracellular Ab at a greatly accelerated rate, 6 and develop the senile plaques characteristic of AD 20-30 years earlier than normal individuals. 71 Elevated plasma Ab is associated with earlier onset of AD. 72 Like FXS, DS patients show mental retardation, craniofacial abnormalities and dendritic dysmorphogenesis. 73 Exacerbated APP production and processing due to increased gene dosage is expected to contribute to disease progression in DS. mGluR 5 expression is also upregulated in DS brain, 74 which could further potentiate the effects of excess Ab.
Autism
Autism spectrum of disorders normally present in the second or third years of life and are characterized by varying degrees of impairment in communication skills, social interactions and restricted, repetitive and stereotyped patterns of behavior. Many autistic children are mentally retarded and half exhibit a marked delay in motor milestones. According to the Centers for Disease Control and Prevention, prevalence is estimated at 1 in 88 children in the US with males five times more likely to be affected than females. Many FXS individuals (67% of males and 23% of females) meet the diagnostic criteria for autism spectrum of disorder. 75 The etiology of autism is unknown, but vaccinations and environmental toxins have been proposed as possible culprits. 76 Children with autism express elevated levels of sAPPa in blood plasma. 77, 78 The highest levels of sAPPa were found in two children with FXS suggesting that the overproduction of sAPPa contributes to the developmental disabilities observed in patients with FXS and autism. 77 It is thought that the increased expression of sAPPa in autism could contribute to brain overgrowth, which is characteristic of the disorder. 79 It is not yet known if the elevated sAPPa is observed in the brain as well as in the periphery. Ab 1-40 , Ab 1-42 and sAPPb levels are significantly decreased in the plasma of severely autistic patients; however, these findings do not extend to patients with mild-to-moderate autism. 79 Lower levels of plasma Ab can indicate sequestration of Ab in the brain in mild cognitive impairment and AD. In total, these data suggest that nonamyloidogenic processing of APP is elevated in severe autism and that the resulting byproduct, sAPPa, contributes to autistic phenotypes; however, brain levels of sAPPa and other APP catabolites remain to be determined.
Epilepsy
Epilepsy is a prevalent neurological disorder characterized by recurrent seizures. The cumulative lifetime risk of unprovoked seizures is 4.1% in the general population with a higher incidence in the elderly. 80 Seizures are a prevalent phenotype in AD (10-22%), 81 FXS (18-23%), 82, 83 DS (8%) 84 and autism (21-38%). 85, 86 Brain injury, infections, tumors, stroke and high fevers are all causes of epilepsy; however, in the majority of cases, the cause is unknown. Epilepsy is considered polygenic and is associated with Figure 2 . APP and Ab expression in neurological disorders. AbPP and Ab levels are altered in the brain (outer trapezoids) and/or blood plasma (inner circle) in AD, FXS, DS, epilepsy, autism and PD as well as in response to brain injury. In the figure, APP and Ab levels are denoted in blue and green, respectively, where up arrows indicate increased levels, down arrows indicate decreased levels and equal signs indicate equivalent levels. In many cases, the levels of specific metabolites have not yet been determined, which is denoted with a '?' . An arrow containing a question mark denotes preliminary data that needs to be independently confirmed. Ab senile plaques are found in autopsied brains of individuals with AD, DS, temporal lobe epilepsy and PD, 71, 89, 91 and Ab deposits can occur as early as 2 h after brain injury. 165 Ab is elevated in the brains of Fmr1 KO mice, 4 but it is not known at this time if Ab plaques are found in FXS or autism. There is a trend for increased Ab in human FXS brain; however, the sample set is not yet large enough to attain statistical significance. 41 In AD blood plasma, levels of Ab can be increased, decreased or unchanged depending on the study, but there is a shift in the Ab 1-42 /Ab 1-40 ratio during disease progression. Plasma Ab 1-42 levels are elevated in patients with mild cognitive impairment, but drop to control levels by the time of AD diagnosis. 166 Plasma Ab 1-42 is decreased in fullmutation FXS males. 41 In DS, elevated plasma Ab is associated with earlier onset of AD 72 and the Ab 1-42 /Ab 1-40 blood plasma ratio is lower than in controls. 107 Thus, a reduced Ab 1-42 /Ab 1-40 blood plasma ratio is found in AD, FXS and DS patients. Ab 1-40 , Ab 1-42 and sAPPb levels are significantly decreased in the plasma of severely autistic patients. 79 Ab 1-40 and Ab 1-42 in plasma are not statistically different between and control and PD or after brain injury. 167, 168 APP levels are increased in blood plasma from AD patients, 169 whereas sAPP levels are decreased in the CSF. 48, 49 There is a strong trend for decreased sAPPa in FXS neocortex and hippocampus albeit the sample size is too small for statistical significance. 41 These data suggest that increased APP levels in the brain in AD and FXS preferentially undergo b-secretase processing resulting in lower a-secretase byproduct. APP is increased in DS brain 170 and the foci of temporal lobe epilepsy, 88 while both sAPPa and sAPPb are elevated in ventricular CSF after brain injury. 168 In blood plasma, sAPPa is elevated in autistic children and DS subjects, but not in full-mutation, adult FXS males. 41, 77, 78, 171 Equivalent sAPPa levels between control and FXS adult plasma samples suggest that APP expression and/or processing decrease with age. Indeed, sAPPa levels are higher in children 7 years and younger than those 10 years and older. 77 Thus, APP and/or its proteolytic derivatives could serve as valuable biomarkers for disease progression and therapeutic efficacy in numerous neurological disorders. mutations in several genes coding for ion channels. 87 APP levels are increased in temporal lobe epilepsy, 88 with 10% of cases exhibiting Ab-immunoreactive senile plaques. 89 As with the aforementioned disorders, it is anticipated that excessive soluble Ab contributes to the severity and progression of epilepsy before the appearance of senile plaques. Ab has a prominent role in synpatic plasticity through inhibition of LTP and activation of LTD so it would not be surprising if altered synaptic levels of Ab altered the excitatory/inhibitory balance of cells causing epileptic activity.
Parkinson's disease PD is the second most common neurodegenerative disease after AD and afflicts about 2% of persons 80 years of age and older. It is characterized clinically by the presence of resting tremor, bradykinesia and rigidity, and pathologically by the loss of pigmented dopaminergic neurons in the substantia nigra and the presence of Lewy bodies and neurites. 90 The loss of dopamine production by neurons in the substantia nigra results in altered communication with the corpus striatum and the inability to control body movements in PD. However, the trigger that starts the cell death process in dopamine neurons is unknown with genetic factors, illness, environmental toxins and aging all implicated. AD pathology is found in a significant percentage of patients with PD. 91 Thus, increased amyloidogenic processing and excess production of sAPPb and Ab could contribute trigger cell death in dopamine neurons in PD.
Psychiatric disorders
The previously described neurological disorders may present with psychiatric symptoms such as anxiety and depression. In dementia patients as well as in cognitively intact elderly individuals living in institutions, exacerbated anxiety, agitation, locomotor activity and delirium during the hours before bedtime has been observed and was named 'sundowning syndrome'. This diurnal pattern of anxiety-like behavior can be studied in rodents where transgenic APP mice exhibit a similar temporal pattern of anxiety-like behavior as elderly mice. 92 We have observed that anxiety in mice, as assessed by center distance travel in an open field, is inversely proportional to App gene dosage. 41 A low plasma Ab 1-42 / Ab 1-40 ratio is associated with an increased risk of developing depression in older individuals with one or more ApoE4 alleles. 93 A cytosine to thymine nucleotide mutation in codon 713 of the APP gene, which produces an alanine to valine change, was found in one patient presenting with schizophrenia. 94 The mutation is located in a critical portion of the APP gene suggesting that it may be pathogenic, albeit the mutation has not yet been detected in other schizophrenics. Thus, APP and Ab could provide a common effector at the molecular level for the neuroanatomical and behavioral phenotypes observed in all of the aforementioned neurological as well as in psychiatric disorders. 95 A common denominator A common denominator in these disorders is the overexpression of APP and/or Ab and a higher propensity for seizure activity. sAPPa is normally neuroprotective and its loss disrupts calcium homeostasis and increases neuronal excitability. 96 Ab is synaptotoxic even in the absence of plaques, 97 and this toxicity in some cell culture models can be inhibited with anticonvulsants. 98 Seizures amplify the synaptic release of Ab thus perpetuating its exocitotoxic effects. 99 Recent studies suggest a bell-shaped relationship between extracellular Ab levels and synaptic transmission in which intermediate levels of Ab enhance presynaptic activity, low levels reduce presynaptic efficacy and high levels enhance LTD. 100 Thus, Ab can act presynaptically as a positive regulator and post-synaptically as a negative regulator to control synaptic activity.
Enhanced LTD is also observed in Fmr1 KO mice and requires rapid mGluR-dependent protein synthesis. 101, 102 41 Ab oligomers bind in a punctate pattern to the dendritic arbor of neurons suggesting that specific synapses are disrupted. 45 Ab selectively depresses excitatory synaptic transmission on neurons that overexpress APP in vitro. 103 These data, in conjunction with the Ab-mediated, protein synthesisdependent, positive feedback loop described earlier, suggest that Ab could activate mGluR 5 signaling in select neurons resulting in increased protein translation of dendritic targets including APP thus providing more target for b-and g-secretase cleavage to produce additional Ab, which exerts synaptotoxic effects through exaggerated dendritic protein synthesis and mGluR-LTD. Thus, mGluR 5 , which is the lead target for drug development in FXS, appears to have a pivotal role in mediating the effects of Ab.
The proposed Ab-mediated positive feedback loop would be initiated by overproduction of Ab. In the case of AD (increased amyloidogenic processing), in the case of DS (increased APP gene dosage) or in the case of FXS (constitutive mGluR 5 signaling) would provide increased interstitial levels of Ab. The molecular switch(es) that turn off the positive feedback loop need to be identified. We hypothesize that FMRP, a translational inhibitor downstream of mGluR 5 , is one of those switches. The ratio of APP catabolites may also be important. Just as the ratio of HDL to LDL as well as absolute levels of the lipoproteins are biomarkers for heart health, it may be necessary to maintain adequate levels of both amyloidogenic and nonamyloidogenic APP catabolites for neurological health. Ab levels in the brain interstitial fluid vary in a diurnal pattern with increased levels observed during the dark period (wakefulness) in AD transgenic mice. 104 Thus, the molecular switches that modulate positive feedback of Ab production may also vary with the circadian cycle and sleep disturbances have been described for the discussed neurological disorders.
BIOMARKERS FOR NEUROLOGICAL HEALTH
The molecular and cellular mechanisms underlying how APP and Ab contribute to disease pathology are under intense investigation by many laboratories. In the future, these proteins will likely serve as valuable biomarkers for neurological health similar to how HDL and LDL levels currently predict cardiovascular health. A reduced Ab 1-42 /Ab 1-40 blood plasma ratio is a putative biomarker for AD, 105 FXS, 41 autism 106 and DS 107 suggesting that the brain acts as a sink for Ab and that lower blood plasma levels indicate increased brain deposition. Alternatively, soluble forms of Ab may mediate neurotoxic effects independent of plaque accumulation and neuronal loss. For example, extracellular accumulation of a 56-Da soluble Ab assembly (Ab*56) elicits memory deficits in middle-age AD model mice. 108, 109 As Ab plaques have not been described in FXS or autism, soluble forms of Ab may mediate disease pathology.
Before APP or Ab can be clinically utilized as biomarkers for neurological disorders, a reliable testing method is required. The Alzheimer's Disease Neuroimaging Initiative is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic and biochemical markers for the early detection and tracking of AD. 110 The development of non-invasive imaging tools for the visualization of soluble and aggregated Ab will aid in early diagnosis and the assessment of therapeutic efficacy. Recent advancements in Ab imaging include radioactive 18 F tracers such as florbetapir and florbetaben, which have proven efficacious in imaging Ab levels in the brains of AD patients by PET scan. 111, 112 In AD mouse models, the existence of Ab plaques in the retina can be individually monitored in real time, 113 and the novel near infrared-fluorescence (NIRF) probe THK-265 can penetrate the blood-brain barrier and bind to cerebral Ab where NIRF signals correlate well with plaque burden. 114 Regarding biological fluid biomarkers, the Alzheimer's Association has initiated a global quality control program to determine why there is large interlaboratory variability in the measurement of AD biomarkers (Ab, total tau and phosphorylated tau) in CSF. 115 We have found that the type of anticoagulant used for blood collection significantly alters blood plasma levels of Ab. 116 Thus, assay platform and sample collection variables will need to be standardized before clinical utilization.
THERAPEUTIC STRATEGIES
Interventions directed at normalizing APP and Ab levels are predicted to attenuate disease phenotypes. Promising therapeutics under study include secretase inhibitors, passive immunotherapy and mGluR 5 antagonists.
Secretase inhibitors b-secretase is a major target for drug development in AD. 117 Continuous administration of a b-secretase inhibitor reduces brain and plasma Ab by 50% and inhibits age-related cognitive decline in an AD mouse model. 118 b-secretase inhibitors are currently in early phase clinical trials. The first description of an orally available b-secretase inhibitor, LY2811376, tested in healthy humans was well tolerated, safe and resulted in prominent and long-lasting Ab reductions in lumbar CSF; albeit clinical trials were halted when off-target effects were observed in longer-term rat preclinical studies. 119 As g-secretase is an essential component of the Notch signaling pathway, the utility of g-secretase inhibitors has been limited by their toxicity. 120 Recent studies demonstrate that a class of diarylaminothiazole drugs modulate, but do not inhibit, g-secretase activity and thereby reduce Ab deposition without some of the toxic side effects associated with the loss of APP and Notch intracellular domains. 121 In addition, the anti-cancer drug Imatinib has been shown to prevent the interaction between gsecretase activating protein and the carboxy-terminal fragment of APP resulting in reduced Ab levels with no affect on Notch cleavage. 122 Thus, these compounds may be viable therapeutic strategies to modulate g-secretase activity without inhibiting Notch activity. Other factors that impact the therapeutic effectiveness of secretase inhibitors are their potency, selectivity and ability to penetrate the blood-brain barrier.
Passive immunotherapy Despite promising results in rodent models, several therapeutics including active Ab vaccines have failed in clinical trials. 123, 124 AD patients immunized with Ab 1-42 showed improvement in cognitive measures, but treatment was discontinued following reports of encephalitis. 125 Thus, the field has moved from active toward passive immunotherapy methods to reduce Ab levels. As the brain is considered an immunoprivileged organ, the prevailing thought is that Ab load is shifted from the CSF to the blood plasma by peripheral administration of anti-Ab antibodies. Anti-Ab improves neurite morphology, synapse density and memory in AD model mice, 126, 127 and ameliorates the neuronal damage induced by pilocarpine-induced seizure activity. 128 Bapineuzumab is a monoclonal anti-Ab vaccine that reduces cerebral Ab burden in patients with AD. 129 Of importance to this therapeutic strategy, over 80% of AD cases 130 and 10% of people beyond 65 years of age 131 exhibit cerebral amyloid angiopathy. Data from human clinical trials and mouse models suggest that passive Ab immunotherapy can redistribute the amyloid burden from the parenchyma to the vasculature leading to microhemorrhages, 132 particularly in patients with the apoliprotein E4 genotype. 133 Thus, passive immunization methods to reduce Ab could be associated with complications in these patient populations. mGluR 5 antagonists The mGluRs are G-protein coupled receptors that are targets for drug therapy in epilepsy, 134 FXS 135, 136 and PD. 137 Agonists acting on group 1 mGluRs (mGluR 1 and mGluR 5 ) are pro-convulsive. In a hippocampal slice model, activation of group 1 mGluRs induces epileptiform discharges, which are prolonged in Fmr1 KO slices. 138 mGluR 5 is predominantly localized to dendritic fields and postsynaptic densities. 139 The subcellular distribution of mGluR 5 varies with postnatal development with movement of the protein toward the distal dendrites and association with synapses. 140 Levels of mGluR 5 are upregulated in DS, autism, epilepsy and PD brain. 74, [141] [142] [143] Levels of mGluR 1 are decreased in area 8 of the frontal cortex and correlated with downregulation of phospholipase C signaling and AD progression, but mGluR 5 levels are unchanged. 144 To our knowledge, there are no reports examining the synaptic location or activity of mGluR 5 in AD. Thus, the inappropriate subcellular localization or activation of mGluR 5 could contribute to seizure propensity.
Group 1 mGluRs regulate the synthesis 4 and metabolism 145 of APP suggesting that inhibition of this pathway could normalize APP and Ab production as well as seizure and behavioral phenotypes associated with amyloid disorders. Indeed, mGluR 5 blockade reduces Ab levels 146 and pentylenetetrazol (PTZ)-induced seizure severity in AD mice, 147 audiogenic seizure incidence in FXS, AD and DS mice, 148, 149 and anxiety phenotypes and dendritic spine protrusion morphology in Fmr1 KO mice. 148, 150 A recent report demonstrates that chronic pharmacological treatment with the brain penetrable mGluR 5 inhibitor CTEP rescues aberrant protein synthesis, synaptic plasticity, cognitive deficits, auditory hypersensitivity, dendritic spine density and overactive MAPK ERK and mTOR signaling in Fmr1 KO mice. 151 It remains to be determined if rescue of these fragile X phenotypes by CTEP is due to normalization of APP and Ab levels.
Other strategies In addition to the discussed interventions, inhibitors of GSK3b, 152 activators of GABA B R 153 and decoy mRNAs, miRNAs and RNA i that reduce APP mRNA and APP expression [154] [155] [156] may also prove beneficial in the treatment of amyloid-related disorders.
CONCLUSION
Accumulating evidence suggests that APP and Ab may serve as valuable biomarkers for neurological health and that therapies directed at normalizing their levels may attenuate disease phenotypes. In order to design rational therapeutics to treat amyloid-related disorders, it is imperative to have a better understanding of the normal physiological functions of APP and Ab at synapses as well as the biochemistry and signaling pathways underlying their production and clearance. Key areas to be addressed include: (1) the consequences of aberrant secretase processing at brain synapses. Still unknown is whether increased nonamyloidogenic processing, which elevates sAPPa, results in altered cell signaling leading to increased synaptogenesis and brain growth in FXS and autism; whether increased amyloidogenic processing at synapses, which produces toxic sAPPb and varied forms of Ab, target-specific cells before plaque accumulation in AD and DS; and whether a balance of amyloidogenic and nonamyloidogenic processing is required to maintain APP and Ab homeostasis with deviations in either direction from this equilibrium promoting neurological disease. For example, will treatments to attenuate amyloidogenic processing without reducing APP production result in excessive sAPPa accumulation and autistic phenotypes? (2) the varied functions of soluble Ab. Increasing evidence suggests that soluble, oligomeric forms of Ab are the pathogenic form of the peptide. 46 It remains to be determined how these oligomeric structures target and functionally disrupt specific synapses, which Ab oligomers are the most important for disease progression, and if those oligomers can serve as reliable biomarkers. And (3) the signaling pathways that mediate the effects of aberrant APP processing. The differential interaction of Ab with mGluR 5 under pathological situations has not yet been determined. It is not known if disease state affects the ability of Ab to induce clustering and activation of mGluR 5 ; if mGluR 5 inhibitors, which are in clinical trials for the treatment of FXS, can restore normal APP synthesis and processing and improve disease phenotypes in the aforementioned disorders; or how receptors other than mGluR 5 are involved. Identification of intracellular signaling molecules that mediate receptor stimulation will provide new therapeutic targets for drug intervention. It is likely that a 'cocktail approach' will be required for treatment as multiple signaling pathways can be simultaneously affected by APP and/or Ab. Reliable biomarkers for the assessment of APP and catabolites in both brain (neuroimaging) and body fluids (ELISA) will be needed to assess therapeutic efficacy.
